Clinical management of drug-drug interactions in HCV therapy: challenges and solutions.

摘要: Hepatitis C virus (HCV) infected patients often take multiple co-medications to treat adverse events related HCV therapy, or manage other co-morbidities. Drug-drug interactions associated with this polypharmacy are relatively new the field of pharmacotherapy. With advent direct-acting antivirals telaprevir and boceprevir, which both substrates inhibitors cytochrome P450 (CYP) 3A iso-enzyme, knowledge awareness drug-drug have become a cornerstone in evaluation starting continuing combination therapy. In our opinion, an overview conducted interaction studies list contraindicated medications is not enough for clinical management these interactions. Knowledge pharmacokinetic profiles concentration-effect relationships key interpretation data, insight into how (e.g., dose adjustments, safe alternatives therapeutic drug monitoring) equal importance. This review provides practical effective challenges.